BACKGROUND: Despite limited evidence of effect, β-blocker continuation has become a national quality improvement metric. OBJECTIVE: To determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. DESIGN, SETTING, AND PATIENTS: The Surgical Care and Outcomes Assessment Program is a Washington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. MAIN OUTCOME MEASURES: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. RESULTS: Of 8431 patients, 23.5% were taking β-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0% were women). Treatment with β-blockers was continued on the day of surgery and during the postoperative period in 66.0% of patients. Continuation of β-blockers both on the day of surgery and postoperatively improved from 57.2% in the first quarter of 2008 to 71.3% in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue β-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40- 25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). CONCLUSIONS: β-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on β-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.
BACKGROUND: Despite limited evidence of effect, β-blocker continuation has become a national quality improvement metric. OBJECTIVE: To determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. DESIGN, SETTING, AND PATIENTS: The Surgical Care and Outcomes Assessment Program is a Washington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. MAIN OUTCOME MEASURES: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. RESULTS: Of 8431 patients, 23.5% were taking β-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0% were women). Treatment with β-blockers was continued on the day of surgery and during the postoperative period in 66.0% of patients. Continuation of β-blockers both on the day of surgery and postoperatively improved from 57.2% in the first quarter of 2008 to 71.3% in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue β-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40- 25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). CONCLUSIONS: β-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on β-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.
Authors: David R Flum; Nancy Fisher; Jeffery Thompson; Miriam Marcus-Smith; Michael Florence; Carlos A Pellegrini Journal: Surgery Date: 2005-11 Impact factor: 3.982
Authors: Franz Wiesbauer; Oliver Schlager; Hans Domanovits; Brigitte Wildner; Gerald Maurer; Marcus Muellner; Hermann Blessberger; Martin Schillinger Journal: Anesth Analg Date: 2007-01 Impact factor: 5.108
Authors: Lee A Fleisher; Joshua A Beckman; Kenneth A Brown; Hugh Calkins; Elliot L Chaikof; Kirsten E Fleischmann; William K Freeman; James B Froehlich; Edward K Kasper; Judy R Kersten; Barbara Riegel; John F Robb Journal: Circulation Date: 2009-11-02 Impact factor: 29.690
Authors: D Poldermans; E Boersma; J J Bax; I R Thomson; L L van de Ven; J D Blankensteijn; H F Baars; T I Yo; G Trocino; C Vigna; J R Roelandt; H van Urk Journal: N Engl J Med Date: 1999-12-09 Impact factor: 91.245
Authors: P J Devereaux; Denis Xavier; Janice Pogue; Gordon Guyatt; Alben Sigamani; Ignacio Garutti; Kate Leslie; Purnima Rao-Melacini; Sue Chrolavicius; Homer Yang; Colin Macdonald; Alvaro Avezum; Luc Lanthier; Weijiang Hu; Salim Yusuf Journal: Ann Intern Med Date: 2011-04-19 Impact factor: 25.391
Authors: P J Devereaux; Homer Yang; Salim Yusuf; Gordon Guyatt; Kate Leslie; Juan Carlos Villar; Denis Xavier; Susan Chrolavicius; Launi Greenspan; Janice Pogue; Prem Pais; Lisheng Liu; Shouchun Xu; German Málaga; Alvaro Avezum; Matthew Chan; Victor M Montori; Mike Jacka; Peter Choi Journal: Lancet Date: 2008-05-12 Impact factor: 79.321
Authors: Martina Teichert; Peter A G M de Smet; Albert Hofman; Jacqueline C M Witteman; Bruno H Ch Stricker Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Valentin Neuhaus; Christiaan H J Swellengrebel; Jeroen K J Bossen; David Ring Journal: Clin Orthop Relat Res Date: 2013-03-01 Impact factor: 4.176
Authors: Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer Journal: Obesity (Silver Spring) Date: 2013-03 Impact factor: 5.002
Authors: Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer Journal: Endocr Pract Date: 2013 Mar-Apr Impact factor: 3.443
Authors: Vlad V Simianu; Arden M Morris; Thomas K Varghese; Michael P Porter; Jeffrey A Henderson; Dedra S Buchwald; David R Flum; Sara H Javid Journal: Am J Surg Date: 2016-01-09 Impact factor: 2.565
Authors: Lovisa Ekestubbe; Gary Alan Bass; Maximilian Peter Forssten; Gabriel Sjölin; Yang Cao; Peter Matthiessen; Rebecka Ahl Hulme; Shahin Mohseni Journal: Sci Rep Date: 2022-03-28 Impact factor: 4.379